 CHARLOTTESVILLE, VA ACCESSWIRE June 17, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW Adial, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has opened clinical trial sites and is recruiting trial subjects in Latvia after receiving all necessary approvals to commence the landmark ONWARDTM pivotal Phase 3 clinical trial in Latvia, including from the State Agency of Medicines of the Republic of Latvia and the Latvian Central Ethics Committee. The ONWARDTM trial is investigating Adials lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. 